Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma

Cancer. 1983 Jan 1;51(1):57-60. doi: 10.1002/1097-0142(19830101)51:1<57::aid-cncr2820510114>3.0.co;2-v.

Abstract

One-hundred and sixteen patients with Stage I and Stage II malignant melanoma were randomized to treatment with either Bacillus Calmette-Guerin (BCG) (Tice) or subcutaneous Corynebacterium parvum (Burroughs-Wellcome). Life table analysis failed to reveal a difference between these two forms of treatment in 68 Stage I patients. The relapse rate was significantly reduced in Stage II patients treated with C. parvum.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • BCG Vaccine / therapeutic use*
  • Bacterial Vaccines / therapeutic use*
  • Evaluation Studies as Topic
  • Female
  • Humans
  • Male
  • Melanoma / therapy*
  • Middle Aged
  • Neoplasm Staging
  • Propionibacterium / immunology*
  • Random Allocation
  • Recurrence
  • Skin Neoplasms / therapy*
  • Time Factors

Substances

  • BCG Vaccine
  • Bacterial Vaccines